Related Experiment Video
Updated: May 25, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Metronomic oral cyclophosphamide in patients with advanced solid tumors
Peter Bojko1, Gudrun Schimmel, Daniel Bosse
1Munich Oncology Practice, MVZ Elisenhof, Munich, Germany. p.bojko@onkologie-elisenhof.de
Background:
Cure is rarely achieved in patients with advanced metastatic solid tumors, and quality of life including times without burdening therapies is an important endpoint. Metronomic oral cyclophosphamide (Cy) has been studied before and is a reasonable option.
Patients And Methods:
24 patients with a mean age of 64.4 years (range 36-82 years) were studied. 18 patients had breast cancer, 4 prostate cancer, 1 uterine carcinoma, and 1 carcinoma of unknown primary.
Results:
All patients had advanced disease with a mean of 2 metastatic sites. Cy was given at a mean dosage of 52 mg daily. Time from diagnosis to start of Cy was 108.6 ± 7.6 months, and from occurrence of metastatic disease to Cy 45.8 ± 45.6 months. Patients had received a mean of 4.2 ± 2.1 prior regimens for metastatic disease. The mean time to treatment failure was 6.4 ± 5.4 months, and mean overall survival was 12.7 ± 7.3 months. Patients received 2.1 ± 1.4 further treatments upon progression. Main toxicities were grade 1 and 2 (n = 25); 3 patients had grade 3 nausea, leucopenia, and elevated gamma glutamyl transferase, respectively.
Conclusion:
Low-dose oral Cy is a reasonable, generally well tolerated, and inexpensive option for patients with advanced solid tumors.
Related Concept Videos
Dosage Regimen: Multiple Oral Dosage
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Oral Drug Delivery Systems: Continuous-Release Systems
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
